Frank Greenway, M.D.Professor--Chief Medical Officer
Clinical Medical Doctor-Greenway
Pharmacology-based Clinical Trials
EDUCATIONB.A. Stanford University, Stanford CA, 1966
M.D., University of California, Los Angeles, CA, 1970
Internal Medicine, Endocrinology/Metabolism, Harbor-UCLA Medical Center, Torrance CA, 1975
RESEARCH INTERESTSDr. Greenway's area of interest is developing obesity treatments including diets, herbal supplements, medical foods, devices, obesity surgery and obesity drug development. He directs the outpatient research clinic.
SELECTED PUBLICATIONSPi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;2;373(1):11-22.
Ammon BS, Bellanger DE, Geiselman PJ, Primeaux SD, Yu Y, Greenway FL. Short-term pilot study of the effect of sleeve gastrectomy on food preference. Obes Surg. 2015;25(6):1094-7
Marinos G, Eliades C, Raman Muthusamy V, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg Obes Relat Dis. 2014;10(5):929-34.
Liu AG, Most MM, Brashear MM, Johnson WD, Cefalu WT, Greenway FL. Reducing the glycemic index or carbohydrate content of mixed meals reduces posprandial glycemia and insulinemia over the entire day but does not affect satiety. Diabetes Care. 2012;35(8):1633-7.
Greenway F, Liu Z, Yu Y, Gupta A. A clinical trial testing the safety and efficacy of a standardized Eucommia ulmoides Oliver bark extract to treat hypertension. Altern Med Rev. 2011;16(4):338-47.
Twiner EM, Liu Z, Gimble J, Yu Y, Greenway F. Pharmacokinetic pilot study of the antiangiogenic activity of standardized platycodi radix. Adv Ther. 2011;28(10):857-65.
Greenway FL, Fujioka K, Plodkowski RA, Mudalair S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-1 Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicenere, randomized, double-blind, placebo-controlled, phase III trial. Lancet 2010;376(9741):595-605.